J&J Agrees To Propulsid Settlement
This article was originally published in The Pink Sheet Daily
Executive Summary
A Johnson & Johnson Propulsid litigation settlement will become effective once 85% of the death claims agree to its terms
You may also be interested in...
‘Open Science’ In Action: Allergan Exercises Option For Motus After Gastroparesis Study
Allergan will pay $200m to exercise its option to buy Motus Therapeutics (formerly Rhythm Health) after what the pharma described as a successful Phase IIb study for relamorelin in diabetic gastroparesis.
J&J To Pay Up To $15 Mil. To Settle Remaining Propulsid Cases
When combined with an earlier settlement agreement, J&J’s total liability for the bulk of the claims will be capped at $105 mil.
J&J To Pay Up To $15 Mil. To Settle Remaining Propulsid Cases
When combined with an earlier settlement agreement, J&J’s total liability for the bulk of the claims will be capped at $105 mil.